清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Stereotactic body radiotherapy combined with lenvatinib with or without PD-1 inhibitors as initial treatment for unresectable hepatocellular carcinoma

伦瓦提尼 医学 肝细胞癌 不利影响 内科学 肿瘤科 联合疗法 放射治疗 卡波扎尼布 索拉非尼 癌症
作者
Quan Wang,Xiaoquan Ji,Jing Sun,Aimin Zhang,Jun Jia,Teng Zhang,Wengang Li,Xuezhang Duan
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier]
标识
DOI:10.1016/j.ijrobp.2024.03.035
摘要

Purpose The aim of this study was to compare the clinical benefit and safety of the triple combination of stereotactic body radiotherapy (SBRT), lenvatinib and programmed death 1 (PD-1) inhibitors with the dual combination of SBRT and lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC). Methods and Materials Patients with uHCC who received SBRT in combination with lenvatinib and PD-1 inhibitors or SBRT in combination with lenvatinib alone as first-line treatment from October 2018 to July 2022 were reviewed in this study. The primary endpoints were overall survival (OS), and progression-free survival (PFS). The second endpoints were intra-hepatic PFS (IHPFS), extra-hepatic PFS (EHPFS) and objective remission rate (ORR). In addition, safety profiles were assessed by analyzing treatment-related adverse events (TRAEs) between the two groups to assess safety profiles. Results In total, 214 patients with uHCC who received combination therapy were included in this retrospective study. Among them, 146 patients received triple combination therapy of SBRT, lenvatinib and PD-1 inhibitors (SBRT-L-P group), and 68 patients received dual therapy of SBRT and lenvatinib (SBRT-L group). The median OS times of the two groups were 31.2 months and 17.4 months, respectively (P<0.001). The median PFS time was significantly longer in the SBRT-L-P group than that in SBRT-L group (15.6 months vs. 8.8 months, p<0.001). Additionally, the median IHPFS (17.5 vs. 9.9 months, p<0.001) and EHPFS (20.9 vs. 11.6 months, p<0.001) were significantly longer in the SBRT-L-P group than that in SBRT-L group. The ORR in the SBRT-L-P group was higher than that in the SBRT-L group (63.0 vs. 39.7%, p=0.002). The incidence and severity of TRAEs in the SBRT-L-P group were comparable to those in the SBRT-L group. Conclusion The use of both lenvatinib and PD-1 inhibitors with SBRT in patients with uHCC was associated with improved overall survival compared to lenvatinib and SBRT alone with a manageable safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Java完成签到,获得积分10
11秒前
ghan完成签到 ,获得积分10
12秒前
catalyst326完成签到,获得积分20
18秒前
21秒前
catalyst326发布了新的文献求助10
28秒前
oaoalaa完成签到 ,获得积分10
42秒前
快乐的七宝完成签到 ,获得积分10
45秒前
47秒前
Alex-Song完成签到 ,获得积分0
49秒前
科研通AI2S应助Singularity采纳,获得10
52秒前
Tiger发布了新的文献求助10
54秒前
隐形曼青应助Singularity采纳,获得10
1分钟前
chichenglin完成签到 ,获得积分10
1分钟前
1分钟前
丁娜发布了新的文献求助10
1分钟前
高高的丹雪完成签到 ,获得积分10
1分钟前
科研通AI2S应助Singularity采纳,获得10
1分钟前
大模型应助spark810采纳,获得10
1分钟前
张丫丫完成签到,获得积分10
2分钟前
丁娜发布了新的文献求助10
2分钟前
2分钟前
金阿垚在科研应助Zitauu采纳,获得10
2分钟前
rosalieshi应助单纯不评采纳,获得30
2分钟前
精壮小伙完成签到,获得积分0
2分钟前
naczx完成签到,获得积分10
3分钟前
丁娜完成签到 ,获得积分10
3分钟前
乐正不愁完成签到,获得积分10
3分钟前
小鱼女侠完成签到 ,获得积分10
3分钟前
3分钟前
单纯不评完成签到,获得积分10
3分钟前
spark810发布了新的文献求助10
3分钟前
福尔摩曦完成签到,获得积分10
3分钟前
启程牛牛完成签到,获得积分0
4分钟前
chen完成签到 ,获得积分10
4分钟前
4分钟前
贝贝完成签到,获得积分0
4分钟前
明亮菀发布了新的文献求助10
4分钟前
花园里的蒜完成签到 ,获得积分0
4分钟前
明亮菀完成签到,获得积分20
4分钟前
高分求助中
Sustainability in ’Tides Chemistry 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
The ACS Guide to Scholarly Communication 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Handbook of the Mammals of the World – Volume 3: Primates 805
Ethnicities: Media, Health, and Coping 800
Gerard de Lairesse : an artist between stage and studio 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3072753
求助须知:如何正确求助?哪些是违规求助? 2726372
关于积分的说明 7493877
捐赠科研通 2374283
什么是DOI,文献DOI怎么找? 1258931
科研通“疑难数据库(出版商)”最低求助积分说明 610434
版权声明 596997